Plexision Secures Funding to Bring Artificial Intelligence to Transplant Outcome Care
PITTSBURGH, July 24, 2025--(BUSINESS WIRE)--Plexision, a biotechnology company, today announced a $365,000 investment from the Richard King Mellon Foundation. The funds will be used to accelerate the integration of artificial intelligence (AI) and machine learning (ML) capabilities across Plexision's suite of cell-based blood tests, significantly improving predictive accuracy for complex transplant outcomes.
Despite advances in transplant medicine, managing immunosuppressive drugs remains a delicate balance. Too little medication can lead to rejection, which can be cell- or antibody-mediated, while too much can increase the risk of infections with different viruses, and in some cases, lymphoma related to Epstein-Barr virus (EBV). Legacy testing tools on the market offer limited visibility into a patient's immune status, and provide reactive, binary results. To distinguish between the various types of rejection and infection, clinicians often integrate other clinical data to make treatment decisions.
Plexision's blood tests predict the most common rejection subtypes and post-transplant infections, all using a common platform of immune cell function. When integrated with machine learning, this test panel ranks risks of multiple outcomes across an outcome category in each patient, including the likelihoods of stable graft function, and T-cell-mediated and antibody-mediated rejection. This approach also identifies the presence or absence of an infection, including infection-related lymphoma. These capabilities have been developed and validated in multi-center studies to be reported at the World Transplant Congress in San Francisco, CA between August 2-6, 2025.
"Plexision is redefining transplant diagnostics by predicting rejection subtypes and infection risks using blood tests derived from a single immune cell function platform," said Dr. Rakesh Sindhi, a transplant surgeon, Co-founder and Chief Scientific Officer, Plexision.
The expanded use of AI will enhance the platform's ability to rank and predict the likelihood of multiple outcomes in each patient, making it a powerful clinical decision support tool for caregivers delivering precision transplant medicine. The company's proprietary technology delivers results in as little as 6 to 24 hours, enabling timely intervention.
"This funding enables us to take the next step in making transplant care truly personalized. By expanding our artificial intelligence and machine learning capabilities, we are transforming how clinicians will interpret immunologic signals, moving from singular binary 'yes/no' answers to ranked predictions tailored to each patient," added Sindhi.
All tests are performed at Plexision's CLIA-approved and CAP-accredited reference laboratory in Pittsburgh, PA, using blood samples shipped in from clinical partners. Results are used with other clinical data to optimize management of individual transplant patients.
Plexision's innovations have demonstrated strong clinical performance. For example, the company's PlexABMR™ test recently predicted antibody-mediated rejection in kidney transplant recipients with 81% positive predictive value and 75% negative predictive value in a multi-center trial. Another test predicted EBV infection, a cause of life-threatening infection-related lymphoma in transplant patients. These findings will also be featured at the 2025 World Transplant Congress.
To learn more about Plexision, visit https://plexision.com/ or email info@plexision.com to schedule a meeting with the company at the World Transplant Congress.
About Plexision
Plexision's reference laboratory performs cell-based blood tests for personalized management of transplant rejection, infections in immunocompromised patients, and immune therapy in oncology. Transplant rejection testing services include the FDA-approved Pleximmune™ blood test to predict transplant rejection in children with liver or intestine transplants, the lab-developed Pleximark™ test to predict kidney transplant rejection, and the recently developed PlexABMR™ to predict antibody-mediated rejection. Tests that predict infection includes the lab-developed PlexCMV™, currently the most sensitive test to capture protective cell-mediated immunity in high-CMV-risk transplants. The PlexEBV™ test predicts EBV infection, which can cause post-transplant lymphoma. These tests measure cell-mediated immunity to cytomegalovirus and EBV, respectively. Plexision also performs custom R & D projects that require integration of cellular biomarker targets in all phases of development of drugs, vaccines, and gene therapy products, from pre-clinical to post-marketing. The company's portfolio of cell-based blood tests can be adapted to assess disease risk for several immunological disorders and develop personalized dosing recommendations. The company's reference laboratory in Pittsburgh, PA, is CLIA-approved, CAP-accredited and GMP-compliant. To learn more, visit www.plexision.com or email info@plexision.com.
About Richard King Mellon Foundation
Founded in 1947, the Richard King Mellon Foundation is the largest foundation in Southwestern Pennsylvania, and one of the 50 largest in the world. The Foundation's 2023 year-end net assets were $2.9 billion, and its Trustees in 2023 disbursed more than $176 million in grants and program-related investments. The Foundation focuses its funding on six primary program areas, delineated in its 2021-2030 Strategic Plan.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250724697940/en/
Contacts
Jason VancuraMarketbridge for Plexisionjvancura@marketbridge.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
What we know about a new health data tracking system being announced by White House
WASHINGTON (AP) — President Donald Trump's planned announcement Wednesday of a new private health tracking system that would make it easier for patients to access their health records and monitor their wellness is raising a host of privacy concerns. The collaboration between the federal government and Big Tech would allow patients to more seamlessly track and share their medical records or data among doctors, hospital systems and health apps, the administration and participating companies say. More details of the system are expected to be announced during a White House event dubbed 'Making Health Technology Great Again' later Wednesday. Here's how it would work The system would be maintained by the federal government through the Centers for Medicare and Medicaid Services. Patients will need to opt in to have their medical records and data shared, which CMS says will be kept secure. Once a patient is in the system, their information could be shared across apps or health systems that have joined the initiative. So, for example, the Apple Health app on your iPhone that tracks your daily step count or your sleep could access lab results from your doctor's office. Putting that information together, the Trump administration says, will offer a fuller picture of your health. The program could start next year The U.S. Department of Health and Human Services says that 60 companies have signed on to work with the system and that they have pledged to 'deliver results to the American people in the first quarter of 2026.' Patient privacy is a top concern Patient advocates and ethicists say many may worry about how their health information – something Americans have long carefully guarded – could be used in ways that they don't want or expect. 'There are enormous ethical and legal concerns,' said Lawrence Gostin, a Georgetown University law professor who specializes in public health. 'Patients across America should be very worried that their medical records are going to be used in ways that harm them and their families.' Also, digital privacy advocates say are skeptical that patients will be able to count on their data being stored securely. 'This scheme is an open door for the further use and monetization of sensitive and personal health information,' said Jeffrey Chester at the Center for Digital Democracy. Amanda Seitz, The Associated Press
CNN
22 minutes ago
- CNN
Candace Cameron Bure reveals her experience with disordered eating
People in entertainment Mental health Food & healthFacebookTweetLink Follow Candace Cameron Bure is opening up about having an eating disorder. The 'Full House' star shared during a recent episode of her podcast that she developed an eating disorder at the age of 18. 'It was binging and purging,' she said, going on to identify herself as 'a bulimic.' Bulimia nervosa is a cyclical condition in which someone binges and then compensates with purging behavior such as vomiting or taking laxatives, according to National Eating Disorders Association. Cameron Bure added that she still refers to herself with that identifier, given that the thoughts never leave her even though she's no longer actively purging. 'So I still need the tools to say, 'No, Candace, we're not doing that,' she said. 'It's so ridiculous, and yet I'm still thinking about it.' Cameron Bure got her start as a child star on 'Full House' and said that her parents kept her and her siblings on diets to prevent them for being criticized for their weight. 'I don't want to be too fat compared to other actors,' she said on her podcast. 'My parents never wanted a producer to come up to me and say, like, 'We need your child to lose weight,' so let's do everything preventative.' Unfortunately, the focus on healthy eating and exercise backfired, Cameron Bure shared. 'That very thing just shaped the way I looked at my body, which was like, 'Oh, it's not good enough the way it is right now,'' she said. Her husband, former hockey player Valeri Bure, has 'been this incredible support' for her even as she struggles with her feelings. 'I feel like a broken record. I'm 49 years old and I'm like, why do I think about this so much? Why does it even matter so much?' Cameron Bure said. CNN's Madeline Holcombe contributed to this report.
Washington Post
22 minutes ago
- Washington Post
What we know about a new health data tracking system being announced by White House
WASHINGTON — President Donald Trump's planned announcement Wednesday of a new private health tracking system that would make it easier for patients to access their health records and monitor their wellness is raising a host of privacy concerns. The collaboration between the federal government and Big Tech would allow patients to more seamlessly track and share their medical records or data among doctors, hospital systems and health apps, the administration and participating companies say. More details of the system are expected to be announced during a White House event dubbed 'Making Health Technology Great Again' later Wednesday. The system would be maintained by the federal government through the Centers for Medicare and Medicaid Services. Patients will need to opt in to have their medical records and data shared, which CMS says will be kept secure. Once a patient is in the system, their information could be shared across apps or health systems that have joined the initiative. So, for example, the Apple Health app on your iPhone that tracks your daily step count or your sleep could access lab results from your doctor's office. Putting that information together, the Trump administration says, will offer a fuller picture of your health. The U.S. Department of Health and Human Services says that 60 companies have signed on to work with the system and that they have pledged to 'deliver results to the American people in the first quarter of 2026.' Patient advocates and ethicists say many may worry about how their health information – something Americans have long carefully guarded – could be used in ways that they don't want or expect. 'There are enormous ethical and legal concerns,' said Lawrence Gostin, a Georgetown University law professor who specializes in public health. 'Patients across America should be very worried that their medical records are going to be used in ways that harm them and their families.' Also, digital privacy advocates say are skeptical that patients will be able to count on their data being stored securely. 'This scheme is an open door for the further use and monetization of sensitive and personal health information,' said Jeffrey Chester at the Center for Digital Democracy.
